NCT03033030

Brief Summary

Breast cancer remains a worldwide big killer with a rate of deaths compared with newly diagnosed cases not lower than 20%. Mammography is the primary imaging modality for the early detection of clinically occult breast cancer. Mammography is established as the primary investigation for population-based breast cancer screening. Advances in mammographic technique regarding both hardware and software applications are still not sufficient to overcome mammography's limitation with regard to both sensitivity and specificity. Depending on several factors, such as age and breast density, mammography screening is associated with a false-negative rate of 10-20 %. Digital Breast Tomosynthesis (TS) is a novel technique that is able to study the breast using 3D reconstructions of the tissue from multiple low-dose digital mammographic images acquired in several planes in a 15 to 50 degree angle. This process aims at a increasing the number of lesion visible due to the reduction of overlapping breast tissue. In TS, to overcome these limitations, a digital mammography (DM) unit is modified to allow the X-ray tube to move through a proscribed arc of excursion acquiring a fixed number of discrete projection images while the breast remains in compression. The individual projection images are extremely low in dose, so the composite dose incurred during a TS acquisition may be similar to that of a standard 2D mammography. The radiologically dense breasts are associated with decreased sensitivity of mammography, both in the clinical and screening setting as well as its established association with breast cancer risk. The systematic application of ultrasound (US) in women with radiologically dense breasts and negative mammogram has been shown to be associated with an additional cancer detection rate \[7,8,9\]. Incremental ultrasound detection of cancer may be considered in the range of 0.27% to 0.52% of ultrasound-screened women in different density categories \[10\]. In addition, the main limitation of US in breast screening is represented by false- positive findings. These findings result in additional investigation or unnecessary surgical biopsy \[10\].

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
8,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2014

Completed
3 years until next milestone

First Submitted

Initial submission to the registry

January 24, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 26, 2017

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2018

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2021

Completed
Last Updated

January 26, 2017

Status Verified

January 1, 2017

Enrollment Period

4.6 years

First QC Date

January 24, 2017

Last Update Submit

January 25, 2017

Conditions

Keywords

UltrasoundDigital Breast TomosynthesisCancer Detection rateSensitivitySpecificityBreast density

Outcome Measures

Primary Outcomes (1)

  • Incremental Cancer Detection Rate or Area Under the Curve

    The study aims to demonstrate at least statistical equivalence, or non-significant difference between TS and US in women with dense breasts.

    2 years

Secondary Outcomes (1)

  • TP/FP rate

    2 years

Study Arms (1)

Tomosynthesis

Patients undergoing Digital Breast Tomosynthesis

Diagnostic Test: Ultrasound

Interventions

UltrasoundDIAGNOSTIC_TEST

Ultrasound examination

Tomosynthesis

Eligibility Criteria

Age18 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Women who undergo breast TS and Mammography

You may qualify if:

  • Asymptomatic subjects \<50 years of age presenting for mammography, with the exception of those that, on previous mammograms are found to have breast density BI- RADS D1-2.
  • Asymptomatic subjects ≥ 50 years of age who request mammography and have breast density BI-RADS 3-4.
  • Written Informed consent.

You may not qualify if:

  • Pregnant and breast feeding women
  • Unable to tolerate breast compression
  • Breast implants
  • Unable to understand or execute written informed consent
  • Unable or unwilling to agree to follow-up during observation period

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UNIGE

Genova, Genova, 16132, Italy

RECRUITING

MeSH Terms

Conditions

Breast NeoplasmsHypersensitivity

Interventions

Ultrasonography

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

Diagnostic ImagingDiagnostic Techniques and ProceduresDiagnosis

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

January 24, 2017

First Posted

January 26, 2017

Study Start

February 1, 2014

Primary Completion

September 1, 2018

Study Completion

September 1, 2021

Last Updated

January 26, 2017

Record last verified: 2017-01

Locations